Global Respiratory Inhaler Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report - Segmented By Product, Technology, Disease Indication & Region - Industry Forecasts (2024 to 2029)

Updated On: January, 2024
ID: 6146
Pages: 175

Global Respiratory Inhaler Market Size (2024 to 2029)

Globally, the size of the respiratory inhaler market is to grow at a CAGR of 4.4% from 2024 to 2029.

A respiratory inhaler is a portable device to administer medications to the lungs. Respiratory disorders have become more common in recent decades for various causes. These respiratory inhalers treat various respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), bronchitis, cystic fibrosis, and other respiratory signs. In 1778, English surgeon and mathematician John Mudge invented the first Inhaler. When patients breathe, the drug is immediately transferred through their lungs, whereas these respiratory inhalers are used with caution and at a precise dosage. Therefore, the dosage of a respiratory inhaler is much lower than in solid or liquid medications. Metered-dose inhalers, dry powder inhalers, and nebulizers are among the different respiratory inhalers available on the market. A metered-dose inhaler (MDI) supplies a fixed dosage of medication to the lungs in the form of a brief blast of aerosolized drug and is often self-administered by the patient by inhalation. A dry-powder inhaler provides medicine as a dry powder to the lungs. On the other hand, a nebulizer converts medicine from a vapor to a spray that patients can inhale through their lungs.


Y-O-Y growth in the prevalence of respiratory disorders is a significant factor driving the growth of the global respiratory inhaler market.

The rising prevalence of respiratory disorders is a significant driver of the respiratory inhaler market's expansion. Respiratory conditions are the primary cause of death and disability worldwide. According to the WHO, asthma infected an estimated 262 million people in 2019 and killed 461000 people. Most asthma-related deaths occur in low- and lower-middle-income countries, where underdiagnosis and under-treatment are challenging. Chronic obstructive pulmonary disease (COPD) affects about 65 million people worldwide and kills 3 million people annually, making it the third leading cause of death. Pneumonia affects millions of people annually and is the primary cause of death in children under 5. Acute lower respiratory tract infections have been among the top three causes of death and injury in children and adults for decades. These patients' symptoms can be controlled with inhalers, but the cure time is shortened. As a result, as the occurrence of respiratory disorders rises, so does the market for inhalers.

Technological advances in respiratory inhalers have increased the global demand for respiratory inhalers.

As the prevalence of respiratory disorders grew, both developed and developing countries started to seek novel inhaler devices, contributing to the increased use of respiratory inhalers. The constant invention of respiratory inhalers and the use of drug sensors that find a way to deliver information directly to a mobile computer such as a P.C. or smartphone is likely to attract users due to its simplicity. This technological breakthrough will positively affect the global respiratory inhaler industry in the coming years. In addition, other technical advances, such as breath actuation, dose monitoring, portability, and feedback mechanisms during treatment, increased system accuracy and inhalation therapy efficacy, raising the market for respiratory inhalers even more.

The government's initiatives to prevent respiratory disorders also boost the growth of the respiratory inhaler market.

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) collaborates with health providers and public health authorities worldwide to increase awareness of the chronic obstructive pulmonary disease (COPD) and improve the prevention and management of this lung disease. Furthermore, the Chronic Respiratory Diseases Awareness Program aims to enhance early diagnosis rates and chronic respiratory disease treatment at both the PHC and population levels. These government policies contribute to more inexpensive drugs, increasing the respiratory inhaler market demand.


A lack of product usage awareness is expected to restrain the growth of the global respiratory inhaler market.

Nonetheless, a lack of understanding about how to use the products limits the development of the respiratory inhaler market. Any error Inhaler uses results in an overdose or a reduced dosage and has severe consequences for the lungs.

Impact of COVID-19 on the global respiratory inhaler market

The coronavirus is a respiratory disease, and the continuing COVID–19 pushed the respiratory inhaler industry to new heights. Millions of patients are hospitalized as a result of coronavirus infection. Furthermore, following the onset of the COVID pandemic, the need for inhalers in ICUs and emergency rooms has increased dramatically. Inhalers are used to improve the drug's efficacy in a broad community of ventilators. In addition, a recent study published in The Lancet journal reported that medical inhalers or inhaled glucocorticoids, which asthma patients widely use, could reduce the risk of severe disease and hospitalization in Covid-19 patients, increasing in demand for respiratory inhalers.

During the pandemic, demand for inhalers increased by 400%, resulting in shortages in the United Kingdom. As demand grows, the producer speeds up production to satisfy the global inhaler demand. Furthermore, the coronavirus pandemic raises awareness of respiratory illnesses, which leads to a rise in the market for respiratory inhalers. Besides that, several countries are now experiencing an oxygen crisis, which raises awareness of respiratory Inhalers. Whereas the COVID-19 pandemic continues, several businesses and policymakers attempt to cure coronavirus using inhaler-based therapy. For example, U.K. hospitals have started a significant trial for a possibly life-saving inhaler-based treatment to save Covid-19 patients from contracting a severe illness. In addition, preliminary data on the phase 3 corticosteroid inhaler reveal that it will shorten the recovery period in COVID-19 patients by three days.




Market Size Available

2023 to 2029

Base Year


Forecast Period

2024 to 2029

Segments Covered

By Product, Technology, Disease Indication, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Market Leaders Profiled

AstraZeneca, Beximco Pharmaceuticals Ltd, Boehringer Ingelheim GmbH, Cipla Ltd, GlaxoSmithKline plc, Koninklijke Philips N.V, Merck & Co., Inc, OMRON Healthcare Europe B.V., PARI Medical Holding, Teva Pharmaceutical Industries Ltd,



Global Respiratory Inhaler Market Analysis By Product

Based on the product type, the metered-dose inhaler (MDI) segment dominates the market with the highest market share, followed by the dry powder inhaler product segment.

Global Respiratory Inhaler Market Analysis By Technology

The manually operated inhaler devices segment occupies the lion's market share based on Technology. In contrast, digitally produced devices will grow at the highest CAGR during the forecast period.

Global Respiratory Inhaler Market Analysis By Disease Indication

Based on disease indication, in 2023, the COPD segment was the market leader and continued the same growing demand throughout the projection period.


As of 2023, North America held a significant share of 41% in the overall respiratory inhaler devices market due to the growing number of COPD disease cases in this Region. Additionally, the United States and Canada markets have grown healthy in North America due to growing product awareness.

Europe was in the 2nd position in leading the majority of the shares in the market. This is because most of the leading manufacturers of respiratory devices are present in European countries, and this cause is providing a required boost for the market to establish itself in this Region.

Besides, the Asia Pacific is to witness the highest growth rate in the coming years. The growing aging population and rising healthcare spending in this Region are helping the respiratory inhaler market to grow.

Regions like Latin America, the Middle East, and Africa have decent growth rates during the forecast period.


Some of the notable companies operating in the global respiratory inhalers market profiled in this report are AstraZeneca, Beximco Pharmaceuticals Ltd, Boehringer Ingelheim GmbH, Cipla Ltd, GlaxoSmithKline plc, Koninklijke Philips N.V, Merck & Co., Inc, OMRON Healthcare Europe B.V., PARI Medical Holding, Teva Pharmaceutical Industries Ltd,


  • On April 09, 2020, Cipla Ltd received the U.S. FDA acceptance for generic Albuterol Sulfate inhalation for treating asthmatic symptoms. It will enhance the strength of the company's position in the market and lead to the launch of many more inhalation products. 
  • On January 08, 2020, Teva Pharmaceuticals developed the digitally integrated Inhaler that the U.S. FDA approved. The device includes sensors where the patient and caregivers can communicate using a mobile app. 
  • In September 2017, the FDA approved GSK's Trelegy Ellipta for people suffering from respiratory problems. It is beneficial for patients suffering from chronic pulmonary obstructive disease.


This research report on the global respiratory inhaler market has been segmented and sub-segmented into the following categories.

By Product

  • Dry Powder Inhaler             
  • Metered Dose Inhaler       
  • Nebulizer 
    • Compressed Air Nebulizers
    • Ultrasonic Nebulizers
    • Mesh Nebulizer

By Technology

  • Manually Operated Inhaler Devices
  • Digitally Operated Inhaler Devices
  • Validation Biomarkers

By Disease Indication

  • Asthma     
  • COPD         
  • Pulmonary Arterial Hypertension  
  • Others Respiratory Disease

By Region

  • North America
    • The United States
    • Canada
    • Rest of North America
  • Europe
    • UK
    • Germany
    • Italy
    • Spain
    • France
    • Rest of E.U.
  • Asia-Pacific
    • India
    • China
    • Japan
    • Australia
    • New Zealand
    • South Korea
    • Rest of APAC
  • Latin America
    • Mexico
    • Brazil
    • Argentina
    • Chile
    • Rest of Latin America
  • Middle East
  • Africa

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1800

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample